Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.36 |
| ▸ | BCL2 | P10415 | 3/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239892 | 0.90 | HTR7 (0.43) | PTGS2PTGS1SIGMAR1MDM2BCL2 | |
| SCHEMBL2949564 | 0.89 | PTGS1 (0.42) | PTGS2PTGS1PPARDMDM2BCL2 | |
| SCHEMBL13239889 | 0.87 | MALT1 (0.46) | PTGS2PTGS1MALT1CYP3A4CYP3A5 | |
| SCHEMBL13239893 | 0.82 | MAPT (0.41) | PTGS2PTGS1PPARDMDM2BCL2 | |
| SCHEMBL13239891 | 0.81 | BCL2 (0.42) | PTGS2PTGS1SIGMAR1CYP3A4MDM2 | |
| SCHEMBL27696188 | 0.80 | PPARD (0.47) | PTGS2PTGS1MALT1PPARD | |
| SCHEMBL13239894 | 0.80 | PPARD (0.41) | PPARDMDM2BCL2MCL1 | |
| SCHEMBL13239845 | 0.79 | PTGS2 (0.41) | PTGS2PTGS1CYP3A4CYP3A5PPARD | |
| SCHEMBL2945886 | 0.78 | PTGS1 (0.42) | PTGS2PTGS1PPARDMDM2BCL2 | |
| SCHEMBL13239883 | 0.77 | MALT1 (0.44) | PTGS2PTGS1MALT1SIGMAR1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-7750032-B2 | Compounds and compositions as PPAR modulators | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137591-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARD, PPARA | PTGS2 669/4885PTGS1 343/4885MALT1 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.